Source: Pharmacy Times articles
Elranatamab shows promising efficacy and manageable safety in transplant-ineligible newly diagnosed multiple myeloma patients, highlighting its potential as a treatment option.
Read More
by MM360 Staff | May 29, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
Elranatamab shows promising efficacy and manageable safety in transplant-ineligible newly diagnosed multiple myeloma patients, highlighting its potential as a treatment option.
Read More